From SNPedia
rs6280, also known as Ser9Gly, is a SNP in the dopamine receptor D3 DRD3 gene. The rs6280(C) allele encodes a glycine, and the (T) allele encodes a serine (in dbSNP orientation).
In a study of 88 patients being treated for schizophrenia with olanzapine, those who were rs6280(C;C) homozygotes had greater positive symptom remission (endpoint rating of minimal or none on all PANSS clinical response positive items, 39.1%), as compared with (C;T) or (T;T) genotypes (13.8%; p = 0.033). [PMID 18320559]
Ser9Gly has been implicated in executive function in some studies, but the results are conflicting.
- [PMID 18351593] Gly/Gly carriers showed significantly (p = 0.002) poorer performance than Ser/Ser carriers on executive functioning tasks in a somewhat small Caucasian sample (84 patients with first-episode psychosis and 85 controls).
- [PMID 2186374] Gly/Ser heterozygotes had 23% more preservative errors on the WCST compared to Ser/Ser homozygotes in a small (216) healthy Han Chinese sample (p = 0.009). Differences between homozygotes were not statistically significant.
- [PMID 15785860] No association between WCST scores and Ser9Gly was found in 138 schizophrenic patients.
[PMID 18348205] Associated in a family association study and pooled sample of 2,037 with nicotine dependence in Americans of European descent.
| ? | (C;C) (C;T) (T;T) |
|---|
 |
[PMID 19358223] The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: A meta-analysis.
| PharmGKB | PA162316713 |
| Name | DRD3: 9 Ser>Gly |
| Annotation | A study on 88 olanzapine-treated patients with schizophrenia found that the Gly/gly genotype was significantly associated with greater positive symptom improvement. |
| Gene | DRD3 |
| Featue | |
| Evidence | PubMed ID:18320559 |
| Drugs | olanzapine |
| Diseases | Schizophrenia |
| Curation Level | Curated |
[PMID 20236178] Dopamine receptor 3(DRD3) polymorphism and risk for migraine
